Xenetic Biosciences Files 10-K/A Amendment 2

Ticker: XBIO · Form: 10-K/A · Filed: May 13, 2025 · CIK: 1534525

Xenetic Biosciences, Inc. 10-K/A Filing Summary
FieldDetail
CompanyXenetic Biosciences, Inc. (XBIO)
Form Type10-K/A
Filed DateMay 13, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: amendment, annual-report, pharmaceuticals

TL;DR

Xenetic Biosciences filed an amendment to its 2024 10-K, adding Part III details.

AI Summary

Xenetic Biosciences, Inc. filed Amendment No. 2 to its Form 10-K for the fiscal year ended December 31, 2024. This amendment primarily includes the information for Part III of the report, which covers items 10-14. The company, formerly known as General Sales & Leasing, Inc. and GENERAL AIRCRAFT INC., is incorporated in Nevada and operates in the Pharmaceutical Preparations sector.

Why It Matters

This filing provides updated information for Part III of Xenetic Biosciences' annual report, which is crucial for investors to understand the company's governance, executive compensation, and security ownership.

Risk Assessment

Risk Level: medium — As a 10-K/A filing, it indicates a company is providing updated or corrected information, which can sometimes signal underlying issues or complexities that warrant closer investor scrutiny.

Key Numbers

  • 2024-12-31 — Fiscal Year End (The period covered by the annual report.)
  • 001-37937 — SEC File Number (The company's registration number with the SEC.)

Key Players & Entities

  • Xenetic Biosciences, Inc. (company) — Registrant
  • December 31, 2024 (date) — Fiscal year end
  • Amendment No. 2 (document_part) — Filing type
  • General Sales & Leasing, Inc. (company) — Former company name
  • GENERAL AIRCRAFT INC. (company) — Former company name
  • Nevada (location) — State of incorporation
  • Framingham, MA (location) — Business address

FAQ

What specific items are included in Part III of this 10-K/A filing?

This Amendment No. 2 to Form 10-K includes items 10-14 of Part III of the report.

What is the fiscal year end date for this report?

The fiscal year ended December 31, 2024.

What is the SEC file number for Xenetic Biosciences, Inc.?

The SEC file number is 001-37937.

What is the primary purpose of filing an Amendment No. 2 to a 10-K?

An Amendment No. 2 to a 10-K is typically filed to provide additional or corrected information for specific sections of the original annual report, in this case, Part III.

What industry does Xenetic Biosciences, Inc. operate in?

Xenetic Biosciences, Inc. operates in the Pharmaceutical Preparations industry, with SIC code 2834.

Filing Details

This Form 10-K/A (Form 10-K/A) was filed with the SEC on May 13, 2025 regarding Xenetic Biosciences, Inc. (XBIO).

View full filing on EDGAR

View Full Filing

View this 10-K/A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.